Company intelligence / Profile preview

Medamonitor

Washington, United Statestrademark.justia.com ↗

Ownership: Private
Development stage: Other

Overview

Medamonitor LLC developed a device to measure breath acetone as a non-invasive biomarker for metabolic states. The company sponsored at least one completed clinical study evaluating the relationship between breath acetone and blood beta-hydroxybutyrate/glucose. It aims to enhance the safety and effectiveness of stimulant medication treatments in response to rising misuse/diversion among youth.

Therapeutic areas: PsychiatryMetabolic Disorders
Modalities: DeviceDigital health tool
Industry: Physiological Monitoring

Beyond the preview

Go deeper on Medamonitor.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Medamonitor.

Explore the full profile